Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.
Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE. Steffin DHM, et al. Among authors: grilley bj. Blood. 2022 Jul 7;140(1):16-24. doi: 10.1182/blood.2022015728. Blood. 2022. PMID: 35325065 Free PMC article.
Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease.
Heslop H, Rooney C, Brenner M, Krance R, Carrum G, Gahn B, Bollard C, Khan S, Gee A, Popat U, Gresik M, Przepiorka D, Kuehnle I, Grilley B. Heslop H, et al. Hum Gene Ther. 2000 Jul 1;11(10):1465-75. doi: 10.1089/10430340050057530. Hum Gene Ther. 2000. PMID: 10910143 Clinical Trial. No abstract available.
Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma.
Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC, Inman S, Cooper K, Alcoser P, Grilley B, Gee A, Popek E, Davidoff A, Bowman LC, Brenner MK, Strother D. Rousseau RF, et al. Blood. 2003 Mar 1;101(5):1718-26. doi: 10.1182/blood-2002-08-2493. Epub 2002 Oct 24. Blood. 2003. PMID: 12406881 Free article. Clinical Trial.
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.
Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK. Rousseau RF, et al. Blood. 2006 Feb 15;107(4):1332-41. doi: 10.1182/blood-2005-03-1259. Epub 2005 Oct 25. Blood. 2006. PMID: 16249392 Free PMC article.
Inducible apoptosis as a safety switch for adoptive cell therapy.
Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Di Stasi A, et al. N Engl J Med. 2011 Nov 3;365(18):1673-83. doi: 10.1056/NEJMoa1106152. N Engl J Med. 2011. PMID: 22047558 Free PMC article. Clinical Trial.
52 results